Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer
- Cohen, EEW
- Licitra, LF
- Burtness, B
- Fayette, J
- Gauler, T
- Clement, Paul
- Grau, JJ
- Del Campo, JM
- Mailliez, A
- Haddad, RI
- Vermorken, JB
- Tahara, M
- Guigay, J
- Geoffrois, L
- Merlano, MC
- Dupuis, N
- Krämer, N
- Cong, XJ
- Gibson, N
- Solca, F
- Ehrnrooth, E
- Machiels, J-PH
Publication date
October 2017
DOI Publisher
Oxford University Press (OUP) Journal
Annals of OncologyAbstract
In the phase III LUX-Head & Neck 1 (LUX-H&N1) trial, second-line afatinib significantly improved progression-free survival (PFS) versus methotrexate in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Here, we evaluated association of prespecified biomarkers with efficacy outcomes in LUX-H&N1.status: publishe
Add to ORKG